1,1,1,3,3,3-六氟-2-丙胺 | 1619-92-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 中文名称: 1,1,1,3,3,3-六氟-2-丙胺
• 英文名称: 2,2,2-Trifluor-1-(trifluormethyl)ethylamin
• 英文别名: α-hydrohexafluoroisopropylamine；1,1,1,3,3,3-hexafluoroisopropylamine；1,1,1,3,3,3-hexafluoropropan-2-amine；2-hydrohexafluoro-2-propanamine；2-H-Hexafluorisopropylamin；2,2,2-Trifluor-1-trifluormethyl-ethylamin
• CAS: 1619-92-7
• 化学式: C₃H₃F₆N
• 分子量: 167.054
• InChiKey: UHEDJBIYIWUMLU-UHFFFAOYSA-N

物化性质

• 沸点：
  58-59 °C
• 密度：
  1.5442 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R34
• 海关编码：
  2921199090
• 危险品运输编号：
  UN 2735

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1,1,1,3,3,3-Hexafluoroisopropylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1,1,1,3,3,3-Hexafluoroisopropylamine
CAS number: 1619-92-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, under −20◦C.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C3H3F6N
Molecular weight: 167.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,1,1,3,3,3-六氟-2-丙胺 在 sodium nitrite 作用下， 以 硫酸 为溶剂， 反应 1.0h， 以72%的产率得到bis(trifluoromethyl)diazomethane
  参考文献：
  名称：

  Sohn, Dieter; Sundermeyer, Wolfgang, Chemische Berichte, 1982, vol. 115, # 10, p. 3334 - 3339

  摘要：

  DOI：
• 作为产物：
  描述：

  1,1,1,3,3,3-六氟-2-丙亚胺 在 lithium aluminium tetrahydride 、 三甘醇二甲醚 作用下， 以68%的产率得到1,1,1,3,3,3-六氟-2-丙胺
  参考文献：
  名称：

  Sohn, Dieter; Sundermeyer, Wolfgang, Chemische Berichte, 1982, vol. 115, # 10, p. 3334 - 3339

  摘要：

  DOI：
• 作为试剂：
  描述：

  2-氟-3-硝基吡啶 、 (1R)-1-(3-methylisoxazol-5-yl)ethanol 在 1,1,1,3,3,3-六氟-2-丙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 3-methyl-5-[(1R)-1-[(3-nitro-2-pyridyl)oxy]ethyl]isoxazole
  参考文献：
  名称：

  SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

  摘要：

  本发明涉及一类新型的.sulfoximine取代喹唑啉衍生物，其通式为I，其中Ar，R1和R2定义如说明和权利要求中所述，以及它们作为MNK1 (MNK1a或MNK1b)和/或MNK2 (MNK2a或MNK2b)激酶抑制剂的应用，包含同一的药物组合物，以及使用它们作为治疗或改善MNK1 (MNK1a或MNK1b)和/或MNK2 (MNK2a或MNK2b)介导的疾病的剂的方法。

  公开号：

  US20150005278A1

文献信息

• POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180297994A1

  公开（公告）日：2018-10-18

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及肌动蛋白M2受体的阳性变构调节剂，特别是新型的7-取代的1-芳基萘啶-3-羧酰胺，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• [EN] 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)<br/>[FR] DÉRIVÉS DE 4-HYDROXYPIPÉRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PROTÉASE 19 SPÉCIFIQUE DE L'UBIQUITINE
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2019150119A1

  公开（公告）日：2019-08-08

  Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.

  提供了公式（I）的泛素特异性蛋白酶19（USP19）的抑制剂，以及包含该抑制剂的药物组合物，以及其使用方法。这些化合物可用于治疗肌肉萎缩、肥胖、胰岛素抵抗或2型糖尿病，或减少肌肉质量的流失。
• An unexpected reaction of diphenyldiazomethane with perfluoro-2-nitrosopropane
  作者：Ronald Eric Banks、Adrian Richards

  DOI：10.1039/c39850000205

  日期：——

  Diphenyldiazomethane reacts with perfluoro-2-nitrosopropane at low temperatures to yield the oxime ether (CF3)2CNOCFPh2, some chemistry of which has been explored.

  二苯基重氮甲烷在低温下与全氟-2-亚硝基丙烷反应，生成肟醚（CF 3）2 C NOCFPh 2，已对其化学性质进行了探索。
• ORGANIC COMPOUNDS
  申请人：Baettig Urs

  公开号：US20100029670A1

  公开（公告）日：2010-02-04

  The present invention relates to compounds of formula (I) wherein X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  本发明涉及以下式（I）的化合物 其中X，R1，R2，R3，R4和R5如本文所定义，这些化合物对于治疗对CXCR2受体介质有响应的疾病是有用的。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORgT
  申请人：Janssen Pharmaceutica NV

  公开号：US20190382373A1

  公开（公告）日：2019-12-19

  The present invention comprises compounds of Formula I. wherein: R 1 , Q, R 3 , R 4 , R 5 , R 6 , A 1 , and A 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明涵盖了Formula I中的化合物，其中：R1、Q、R3、R4、R5、R6、A1和A2在规范中有定义。该发明还涵盖了一种治疗或改善ROR-γ-t介导的综合征、疾病或疾病的方法，包括综合征、疾病或疾病选自风湿性关节炎、银屑病性关节炎和银屑病的群体。该发明还涵盖了通过给哺乳动物施用至少一种Formula I化合物的治疗有效量来调节RORγt活性的方法。